Riederer P, Horowski R
J Neural Transm (Vienna). 2023; 130(11):1323-1335.
PMID: 37796288
PMC: 10645634.
DOI: 10.1007/s00702-023-02692-9.
Shi L, Huang C, Luo Q, Xia Y, Liu W, Zeng W
Aging (Albany NY). 2020; 12(10):9515-9533.
PMID: 32424108
PMC: 7288933.
DOI: 10.18632/aging.103225.
Farvardin M, Khalili M, Behnia M
J Ophthalmic Vis Res. 2019; 14(4):457-464.
PMID: 31875101
PMC: 6825694.
DOI: 10.18502/jovr.v14i4.5451.
Schreurs A, Versteeg D, Nijkamp F
Naunyn Schmiedebergs Arch Pharmacol. 1982; 320(3):235-9.
PMID: 6290901
DOI: 10.1007/BF00510134.
Stromberg U
Psychopharmacologia. 1970; 18(1):58-67.
PMID: 5535577
DOI: 10.1007/BF00402384.
Distribution and metabolism of L-3-O-methyldopa in rats.
BARTHOLINI G, Kuruma I, Pletscher A
Br J Pharmacol. 1970; 40(3):461-7.
PMID: 5497794
PMC: 1703137.
DOI: 10.1111/j.1476-5381.1970.tb10627.x.
L-dopa treatment failure: explanation and correction.
Dujovne C, Morgan J, Lasagna L, BIANCHINE J
Br Med J. 1970; 4(5727):93-4.
PMID: 5482325
PMC: 1819624.
DOI: 10.1136/bmj.4.5727.93.
The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopa.
Curzon G, Godwin-Austen R, Tomlinson E, Kantamaneni B
J Neurol Neurosurg Psychiatry. 1970; 33(1):1-6.
PMID: 5418176
PMC: 493400.
DOI: 10.1136/jnnp.33.1.1.
[The capillary barrier for dopa in brain and different organs].
Constantinidis J, de la Torre J, Tissot R, GEISSBUHLER F
Psychopharmacologia. 1969; 15(2):75-87.
PMID: 5351123
DOI: 10.1007/BF00407039.
Effects of L-dopa on norepinephrine metabolism in the brain.
Chalmers J, Baldessarini R, Wurtman R
Proc Natl Acad Sci U S A. 1971; 68(3):662-6.
PMID: 5276777
PMC: 389012.
DOI: 10.1073/pnas.68.3.662.
Storage, uptake and synthesis of catecholamines in the intrinsic adrenergic neurones in the proximal colon of the guinea-pig.
Costa M, Furness J
Z Zellforsch Mikrosk Anat. 1971; 120(3):364-85.
PMID: 5153841
DOI: 10.1007/BF00324898.
Passage into the rat brain of dopa and dopamine injected into the lateral ventricle.
Constantinidis J, Gaillard J, GEISSBUHLER F, Tissot R
Br J Pharmacol. 1971; 43(1):32-8.
PMID: 5136462
PMC: 1665926.
DOI: 10.1111/j.1476-5381.1971.tb07154.x.
The effect of L-DOPA on brain catecholamines and motility in rats.
Maj J, Grabowska M, Mogilnicka E
Psychopharmacologia. 1971; 22(2):162-71.
PMID: 5124189
DOI: 10.1007/BF00403624.
L-DOPA induced effects on motor activity in mice after inhibition of dopamine-beta-hydroxylase.
Stromberg U, Svensson T
Psychopharmacologia. 1971; 19(1):53-60.
PMID: 5089105
DOI: 10.1007/BF00403702.
The mode of action of -methyldopa.
DAY M, Roach A, Whiting R
Br J Pharmacol. 1972; 45(1):168P-169P.
PMID: 5041485
PMC: 1666180.
Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease.
Barbeau A, MARS H, Botez M, Joubert M
Can Med Assoc J. 1972; 106(11):1169-74.
PMID: 5034697
PMC: 1940581.
Peripheral aromatic L-amino acids decarboxylase inhibitor in Parkinsonism. I. Effect on O-methylated metabolites of L-dopa-2- 14 C.
Messiha F, Hsu T, BIANCHINE J
J Clin Invest. 1972; 51(2):452-5.
PMID: 5009125
PMC: 302144.
DOI: 10.1172/JCI106831.
[Comparison of the effect of L-Dopa and of an L-Dopa+decarboxylase inhibitor combination in Parkinson's disease].
Schneider E, FISCHER P, Jacobi P, MAXION H
Arch Psychiatr Nervenkr (1970). 1973; 217(1):95-112.
PMID: 4695662
DOI: 10.1007/BF02552835.
Brocresine in Parkinson's disease. Action of a peripheral and central decarboxylase inhibitor in potentiating levodopa.
Howse P, Matthews W
J Neurol Neurosurg Psychiatry. 1973; 36(1):27-9.
PMID: 4570903
PMC: 494271.
DOI: 10.1136/jnnp.36.1.27.
Effects of a decarboxylase inhibitor on the Dopa and 5-HTP induced changes in the locomotor-like discharge pattern of rabbit hind limb nerves.
Viala D, Buser P
Psychopharmacologia. 1974; 40(3):225-33.
PMID: 4548539
DOI: 10.1007/BF00429416.
